摘要
目的:研究羟基喜树碱与吡柔比星联合应用对膀胱癌5637细胞生长的抑制作用。方法:将所培养的5637细胞分为五组,未加药5637细胞组、羟基喜树碱(HCPT)单药组、吡柔比星(THP)单药组、先羟基喜树碱后吡柔比星联合用药组、先吡柔比星后羟基喜树碱联合用药组。用RT-PCR检测残存细胞所表达的耐药基因(mrp-4,mrp-1,mdr-1),用MTT方法测定各组细胞的抑制情况。结果:联合使用对5637细胞增殖抑制作用优于单药THP和HCPT对肿瘤细胞的抑制作用。单用HCPT,残存的细胞中表达mrp-1和mdr-1。单用THP,残存的细胞中表达mrp-4和mdr-1。联合使用HCPT和THP后,残存细胞中仅表达mdr-1,两者联合应用起到了降低肿瘤细胞耐药性的目的。结论:HCPT和THP联合用于膀胱内灌注化疗具有联合化疗用药的合理性。
Objective：To study the inhibitory effect of hydroxycamptothecin（HCPT） combined with pirarubicin （THP） in human bladder cancer cell line 5637. Methods：The inhibitory effects of HCPT, THP and HCPT combined with THP on bladder cancer cell line 5637 were determined by MTT assay. And we detected the multidrug resistance （MDR） gene by RT-PCR. Results：The inhibitory effect was found when these two drugs were used alone or together. When used together, it showed the better inhibitory effect in human bladder cancer cell line 5637 than used alone bt either drug. When only used HCPT, we found the expression of mrp-1 and mdr-1 genes. When only used THP, we found the expression of mrp-4 and mdr-1 genes. When used together, we only found the expression of mdr-1 gene. Conclusions： The combined administration of HCPT and THP showed better inhibitory effects along with fewer MDR gene expression. It indicated that combined HCPT and THP administration might have the better clinical results for superficial bladder cancer patient.
出处
《临床泌尿外科杂志》
2008年第8期617-620,629,共5页
Journal of Clinical Urology
关键词
膀胱癌
羟基喜树碱
吡柔比星
多药耐药
Bladder cancer
Hydroxycamptothecin
Pirarubicin
Multidrug resistance
作者简介
[通讯作者]沈海波（E-mail：haibo．shen@gmail．com）
